Engineered immune cells take on Hard-to-Treat lymphoma in new trial
NCT ID NCT07473167
First seen Mar 16, 2026 · Last updated May 19, 2026 · Updated 10 times
Summary
This study tests a new treatment called TC011, which uses a patient's own immune cells modified to find and attack cancer cells. It is for adults with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The trial aims to find the safest dose and measure how well the therapy shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, Seoul, 03080, South Korea
Contact
Conditions
Explore the condition pages connected to this study.